Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 3 - The Real Truth

Is Biogen Stock Underperforming the Dow?

Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Revolution Or Mirage? Controversy Surrounds New Alzheimer's Drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

International Business Times

Is Wall Street Bullish or Bearish on Biogen Stock?

Despite Biogen’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Biogen Earnings Preview: What to Expect

Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

Is Biogen Stock Underperforming the Nasdaq?

Biogen underperforms the Nasdaq Composite, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Biogen And Ionis Halt ALS Treatment Development

Biogen and Ionis discontinue ALS treatment development, emphasizing the need for continued research in neurodegenerative diseases.

Top News

People with MND in England and Wales fear losing access to life-extending drug

NHS cost threshold has not been raised by National Institute for Health and Care Excellence since 2004

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.18% and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.53%. Stock indexes on Friday gave up early gains and closed moderately lower. Stocks on...

Barchart

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

International Business Times

5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

Barchart

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com

Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

StockNews.com

Biogen Pulls Controversial Alzheimer's Drug Aduhelm

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

International Business Times

Patent monopolies are not "free" market

Drug patent monopolies cost each family $5,000 per year

Salon

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Salon

Do new Alzheimer's drugs actually help?

Fast-track approval of three risky drugs intends to slow the disease, but evidence they benefit patients is shaky

Salon

FDA approves postpartum depression pill

Here’s what we know about the second drug to ever be approved for the post-pregnancy condition

Get all your
news in one place.

100's of premium titles.
One news app.

Zenger

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Axios

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

Roll Call

FDA grants full approval to new Alzheimer’s drug - Roll Call

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Fortune

Fortune 500 companies and CEOs react to end of affirmative action

Fortune 500 companies, including Salesforce and Microsoft, reacted to the Supreme Court's decision to reject affirmative action at U.S. colleges and universities.

StockNews.com

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

Barchart

Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data

June S&P 500 futures (ESM23) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.16% this morning as market participants braced for the Federal Reserve’s interest rate decision while also awaiting crucial U.S. PPI data.

Barchart

Stocks Rally on Expectations the Fed Will Pause Rate Hikes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.69%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IU XX) (QQQ ) closed up +0.79%. Stock indexes on Tuesday finished moderately higher, with the...

1 2 3 4 5

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.